Abciximab

阿昔单抗

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAbciximab
Drug Alias Name阿布赛昔单抗CentoRxabciximab (Johnson & Johnson)阿西单抗abciximabum (Johnson & Johnson) +[11] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragment
Mechanisms of ActionIntegrin alpha-IIb/beta-3 antagonists
TargetsIntegrin alpha-IIb/beta-3
Therapy Area/IndicationsAcute DiseaseConstriction, PathologicArterial Occlusive Diseases +[11] 
Global Approved IndicationsMyocardial Ischemia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1994/12/22
Country/TerritoryUnited StatesGermanySwitzerland +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson Innovative MedicineEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesJanssen Biotech Inc
Inactive CompaniesUniversity of ZurichUniversity Of RochesterEli Lilly And Company +[8] 
Active IndicationsMyocardial Ischemia
Inactive IndicationsAcute DiseaseConstriction, PathologicArterial Occlusive Diseases +[10] 

Other Information

ATC CodeB01AC13
Related LinksWikipediaDrugBankKEGG